B-cell receptor

From Wikipedia, the free encyclopedia
Jump to: navigation, search
The B-cell receptor includes both CD79 and the immunoglobulin. The plasma membrane of a B cell is indicated by the green phospholipids. The B cell receptor extends both outside the cell (above the plasma membrane) and inside the cell (below the membrane).

The B-cell receptor or BCR is a transmembrane receptor protein located on the outer surface of B-cells. The receptor's binding moiety is composed of a membrane-bound antibody that, like all antibodies, has a unique and randomly determined antigen-binding site. When a B-cell is activated by its first encounter with an antigen that binds to its receptor (its "cognate antigen"), the cell proliferates and differentiates to generate a population of antibody-secreting plasma B cells and memory B cells. The B cell receptor (BCR) has two crucial functions upon interaction with Ag. One function is signal transduction, involving changes in receptor oligomerization. The second function is to mediate internalization for subsequent processing of Ag and presentation of peptides to helper T cells. BCR functions are required for normal antibody production, and defects in BCR signal transduction may lead to immunodeficency,[1] auto-immunity[2] and B-cell malignancy.[3]

Components of the B-cell receptor[edit]

The B-cell receptor is composed of two parts:[4]

  1. Ligand binding moiety: A membrane-bound immunoglobulin molecule of one isotype (IgD, IgM, IgA or IgE). With the exception of the presence of an integral membrane domain, these are identical to their secreted forms.
  2. Signal transduction moiety: A heterodimer called Ig-α/Ig-β (CD79), bound together by disulfide bridges. Each member of the dimer spans the plasma membrane and has a cytoplasmic tail bearing an immunoreceptor tyrosine-based activation motif (ITAM).

Signaling pathways of the B-cell receptor[edit]

There are several signaling pathways that the B-Cell Receptor can follow through. Of those known, there can be intracellular signaling through the PLCy/calcium/NFAT pathway, the PI3K pathway, the IKK/NF-κB pathway, and canonical ERK pathway.[5] These processes can be regulated by non-coding RNAs, like microRNAs.[6]

  1. IKK/NF-κB Transcription Factor Pathway: CD79 and other proteins, microsignalosomes, go to activate PLC-γ after antigen recognition by the BCR and before it goes to associate into the c-SMAC. It then cleaves PIP2 into IP3 and DAG (diacylglycerol). IP3 acts as a second messenger to dramatically increase ionic calcium inside the cytosol (via release from the endoplasmic reticulum or influx from the extracellular environment via ion channels). This leads to eventual activation of PKCβ from the calcium and DAG. PKCβ phosphorylates (either directly or indirectly) the NF-κB signaling complex protein CARMA1 (the complex itself comprising CARMA1, BCL10, and MALT1). These result in recruitment and summoning of the IKK (IkB kinase), TAK1 by several ubiquitylation enzymes also associated with the CARMA1/BCL10/MALT1 complex. MALT1 itself is a caspase-like protein that cleaves A20, an inhibitory protein of NF-κB signaling (which acts by deubiquitylating NF-κB’s ubiquitylation substrates, having an inhibitory effect). TAK1 phosphorylates the IKK trimer after it too has been recruited to the signaling complex by its associated ubiquitylation enzymes. IKK then phosphorylates IkB (an inhibitor of and bound to NF-κB), which induces its destruction by marking it for proteolytic degradation, freeing cytosolic NF-κB. NF-κB then migrates to the nucleus to bind to DNA at specific response elements, causing recruitment of transcription molecules and beginning the transcription process.[5]

The B-cell receptor in malignancy[edit]

The B-cell receptor has been shown to be involved in the pathogenesis of various B cell-derived lymphoid cancers.[6] Although it may be possible that stimulation by antigen binding contributes to the proliferation of malignant B cells,[7] increasing evidence implicates antigen-independent self-association of BCRs as a key feature in a growing number of B-cell neoplasias.[8][9][10][11] B-cell receptor signalling is currently a therapeutic target in various lymphoid neoplasms.

References[edit]

  1. ^ Conley, Mary Ellen; A. Kerry Dobbs; Dana M. Farmer; Sebnem Kilic; Kenneth Paris; Sofia Grigoriadou; Elaine Coustan-Smith; Vanessa Howard; Dario Campana (2009). "Primary B cell immunodeficiencies: comparisons and contrasts". Annual Review of Immunology 27. doi:10.1146/annurev.immunol.021908.132649?url. 
  2. ^ Goodnow, Christopher (2007). "Multistep pathogenesis of autoimmune disease". Cell 130 (1): 25–35. doi:10.1016/j.cell.2007.06.033. PMID 17632054. 
  3. ^ Corcos, D; MJ Osborn; LS Matheson (2011). "B-cell receptors and heavy chain diseases: guilty by association?". Blood 117 (26): 6991–8. doi:10.1182/blood-2011-02-336164. PMID 21508409. 
  4. ^ Kindt, Thomas J.; Goldsby, Richard A.; Osborne, Barbara A.; Kuby, Janis (2007). Kuby immunology. New York: W.H. Freeman. ISBN 1-4292-0211-4. 
  5. ^ a b Kurosaki, Tomohiro; Hisaaki Shinohara; Yoshihiro Baba (2008). "B Cell Signaling and Fate Decision". Annual Review of Immunology 28 (1): 21. doi:10.1146/annurev.immunol.021908.132541. 
  6. ^ a b Mraz, M.; Kipps, T. J. (2013). "MicroRNAs and B Cell Receptor Signaling in Chronic Lymphocytic Leukemia". Leukemia & Lymphoma 54 (8): 1836–9. doi:10.3109/10428194.2013.796055. PMID 23597135.  edit
  7. ^ Daneshek, W; RS Schwartz (1959). "Leukemia and auto-immunization- some possible relationships". Blood 14. 
  8. ^ Corcos, D (1990). "Oncogenic potential of the B-cell antigen receptor and its relevance to heavy chain diseases and other B-cell neoplasias: a new model". Res Immunol. 141 (6): 543–53. doi:10.1016/0923-2494(90)90022-Q. PMID 2284498. 
  9. ^ Corcos D, Dunda O, Butor C et al. (1995). "Pre-B-cell development in the absence of lambda 5 in transgenic mice expressing a heavy-chain disease protein". Curr. Biol. 5 (10): 1140–8. doi:10.1016/S0960-9822(95)00230-2. PMID 8548286. 
  10. ^ Davis, RE; Ngo, Vu N.; Lenz, G; Tolar, P; Young, RM; Romesser, PB; Kohlhammer, H; Lamy, L; Zhao, H; Yang, Y; Xu, W; Shaffer, AL; Wright, G; Xiao, W; Powell, J; Jiang, JK; Thomas, CJ; Rosenwald, A; Ott, G; Muller-Hermelink, HK; Gascoyne, RD; Connors, JM; Johnson, NA; Rimsza, LM; Campo, E; Jaffe, ES; Wilson, WH; Delabie, J; Smeland, EB; Fisher, RI; Braziel, RM; Tubbs, RR; Cook, JR; Weisenburger, DD; Chan, WC; Pierce, SK; Staudt, LM (2010). "Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma". Nature 463 (7277): 88–92. Bibcode:2010Natur.463...88D. doi:10.1038/nature08638. PMC 2845535. PMID 20054396. 
  11. ^ Dühren-von Minden M; Übelhart R; Schneider D; Wossning T; Bach MP; Buchner M; Hofmann D; Surova E; Follo M; Köhler F; Wardemann H; Zirlik K; Veelken H; Jumaa H (2012). "Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling". Nature 489 (7415): 309–312. Bibcode:2012Natur.489..309M. doi:10.1038/nature11309. PMID 22885698. 

External links[edit]